

# Gillian A Horne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2270693/publications.pdf>

Version: 2024-02-01

13  
papers

220  
citations

1477746

6  
h-index

1125271

13  
g-index

14  
all docs

14  
docs citations

14  
times ranked

405  
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. <i>Journal of Clinical Medicine</i> , 2020, 9, 2934.	1.0	57
2	A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. <i>Leukemia</i> , 2020, 34, 1775-1786.	3.3	49
3	CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. <i>Leukemia</i> , 2020, 34, 1613-1625.	3.3	46
4	Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , 2022, 9, e121-e132.	2.2	21
5	Approaches for targeting self-renewal pathways in cancer stem cells: implications for hematological treatments. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 465-474.	2.5	12
6	CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia. <i>Blood</i> , 2015, 126, 49-49.	0.6	9
7	The psychological impact of COVID19 on a shielding high-risk cohort. <i>Scottish Medical Journal</i> , 2020, 65, 120-122.	0.7	8
8	Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. <i>Advances in Biological Regulation</i> , 2021, 82, 100830.	1.4	8
9	Trial re-investment to build better research for better impact. <i>Lancet, The</i> , 2019, 394, 635-636.	6.3	2
10	Multiple myeloma: therapeutic delivery of antibodies and aptamers. <i>Therapeutic Delivery</i> , 2021, 12, 705-722.	1.2	2
11	Implications of CAR-T cell therapy on apheresis services: a Scottish perspective. <i>Journal of Clinical Apheresis</i> , 2021, 36, 513-515.	0.7	2
12	Notch Pathway Activation Targets Leukemic Stem Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML). <i>Blood</i> , 2016, 128, 3057-3057.	0.6	1
13	Haemolytic anaemia: don't leave it out in the cold. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2015, 100, 323-330.	0.3	0